Press Releases & News Archives - Page 6 of 7 - Triumvira Immunologics | Engineered T Cell Therapies

TAC technology shows efficacy, safety, and TAC-T cell persistence in preclinical models of liquid and solid tumors

AUSTIN, TX, and HAMILTON, ON, August 30, 2018 – Triumvira Immunologics, Inc. (Triumvira), a privately-held biopharmaceutical company focused on designing safe and more effective T cell therapies, will present data today on its novel T cell therapy technology, TAC-T, during an oral presentation in the Adoptive T Cell Therapies session of the 6th Annual Immuno-Oncology Summit held in Boston. The presentation will describe the differentiated mechanism of action of the company’s T cell antigen coupler (TAC) technology in preclinical studies demonstrating strong efficacy in both solid and liquid tumors with an improved safety profile compared to traditional CAR-T approaches.

The oral presentation, entitled: TAC-T: a novel T cell therapy, co-opts the endogenous T cell receptor for effective, safe, and persistent tumor rejection, will be delivered by Christopher Helsen, PhD, Director of Research and Development at Triumvira. Results from pre-clinical studies with human T cells engineered with Triumvira’s proprietary TAC technology directed against different antigens will be presented. The data suggest that TAC-T cells destroy tumor cells via a mechanism that mimics the natural process of T cell activation. Results clearly demonstrate efficient infiltration and proliferation in solid tumors resulting in rapid and sustained tumor regression in mice without toxicity. Furthermore, in a xenograft model of multiple myeloma, treated mice showed resistance to tumor re-challenge indicating long-term persistence of TAC-T cells.

“These results will further illustrate the potential of TAC-T cells, both in terms of efficacy and safety but also with respect to TAC T-cell persistence, a key point under consideration in T cell therapy,” said Paul Lammers, MD, MSc, President and Chief Executive Officer.

Triumvira also announces it is participating in the 11th Annual International Partnering Conference BioPharm America on September 5-6 and the 4th Annual CAR-TCR Summit 2018 – Changing Lives with CAR-T & TCR Cell Immunotherapies on September 4-5, both being held during Biotech Week Boston. For more information, or to set up a meeting with Triumvira at either conference email: partners@triumvira.com

About Triumvira Immunologics

Triumvira Immunologics, Inc. is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current cell therapy cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Our proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the Major Histocompatibility Complex (MHC), allowing for the development of better therapies for a broader range of patients with either solid or liquid malignancies and with diseases other than cancer. With operations spanning North America, our corporate offices are located in Austin, Texas, and our research facilities in Hamilton, Ontario. For more information, visit www.triumvira.com or send email inquiries to partners@triumvira.com

BCMA-TAC cells induce remission/ show persistence in Multiple Myeloma xenograft model (KMS11-NanoLuc)

click image for larger version

Efficacy of Engineered T Cells can be Uncoupled from Toxicities Observed with CAR T Cell Therapy

AUSTIN, TX, and HAMILTON, ON, August 3, 2018 – Triumvira Immunologics, Inc., (Triumvira) a privately-held biopharmaceutical company focused on designing safe and more effective T cell therapies today announced the publication of a peer-reviewed article in today’s edition of Nature Communications, which describes the mechanism of action of the company’s T cell antigen coupler (TAC) technology, designed to co-opt the natural biology of T cells to attack solid and liquid tumors.

The article, titled “The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity” presents results from pre-clinical studies with human T cells engineered with Triumvira’s proprietary TAC technology directed against multiple antigens. The results clearly demonstrate robust and antigen-specific cytokine production and cytotoxicity in vitro and strong anti-tumor activity in a variety of xenograft models, including solid and liquid tumors. In addition, the study observes that HER2-TAC T cells demonstrate robust penetration and local proliferation and activation in solid tumors.

“This peer-reviewed article provides scientific validation of our platform TAC technology and provides future hope for patients by potentially making T cell therapy more accessible to a much larger pool of cancer patients,” commented Paul Lammers, MD, MSc, President and Chief Executive Officer.

“Comparative studies in a solid tumor model demonstrated the unique biological differences of the TAC and CAR receptors. Unlike the known toxicities with CAR T cell therapy, this study indicated that TAC T cells outperformed second-generation CAR T cells, revealing both increased tumor penetrating ability, anti-tumor efficacy and reduced toxicity,” commented Jonathan Bramson, PhD, Professor of Pathology and Molecular Medicine, Vice Dean for Research at McMaster University, Hamilton, ON, Canada, and Triumvira’s co-founder and Acting Chief Scientific Officer.

Innovative immuno-therapy company welcomes former President and COO of Celgene

AUSTIN, Texas & TORONTO–(BUSINESS WIRE)–Triumvira Immunologics, Inc., a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack cancers, today announced the appointment of Scott Smith to the Board of Directors.

“We are thrilled to welcome Scott to the Triumvira Board of Directors,” said President and CEO of Triumvira Immunologics, Dr. Paul Lammers. “Scott’s leadership experience in immunology and oncology, together with his commercial operations expertise, will be instrumental as we build our company and work to bring new treatments to patients in need through our proprietary T Cell-Antigen Coupler (TAC) technology.”

Brings 30-years of Experience to Company’s Technology Development and Manufacturing Operations

AUSTIN, Texas–(BUSINESS WIRE)–Triumvira Immunologics, a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack cancers, today announced the appointment of Donna Rill as Chief Technology Officer.

As CTO, Rill will use her extensive technology development and manufacturing experience to help drive Triumvira’s clinical development programs.

About Triumvira Immunologics Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current gene therapy cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Our proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the Major Histocompatibility Complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and with diseases other than cancer.

For more information LaVoieHealthScience
Beth Kurth
Vice President, Investor Relations & Corporate Communications
Phone: +1 617 374 8800, Ext. 106
bkurth@lavoiehealthscience.com